FY2025 EPS Estimates for ESPR Increased by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald raised its FY2025 earnings per share (EPS) estimate for Esperion Therapeutics from $0.09 to $0.21, while also predicting $0.23 EPS for FY2026.
• Despite reporting a quarterly EPS of ($0.02), Esperion exceeded the consensus estimate of ($0.17) and generated $82.39 million in revenue, significantly higher than the expected $62.55 million.
• Investment analysts have mixed ratings on Esperion, with two holding a "hold" rating and four assigning a "buy" rating, leading to a consensus rating of "Moderate Buy" with a price target of $7.00.

Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) - Research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a report issued on Wednesday, August 6th. Cantor Fitzgerald analyst K. Kluska now expects that the biopharmaceutical company will earn $0.21 per share for the year, up from their previous forecast of $0.09. The consensus estimate for Esperion Therapeutics' current full-year earnings is ($0.29) per share. Cantor Fitzgerald also issued estimates for Esperion Therapeutics' FY2026 earnings at $0.23 EPS.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.15. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%. The firm had revenue of $82.39 million for the quarter, compared to the consensus estimate of $62.55 million.

A number of other brokerages have also recently commented on ESPR. The Goldman Sachs Group dropped their price objective on shares of Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and issued a $16.00 price target on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. Finally, Needham & Company LLC decreased their price objective on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Esperion Therapeutics has a consensus rating of "Moderate Buy" and a consensus price target of $7.00.

Esperion Therapeutics Stock Performance

ESPR opened at $1.72 on Friday. The stock has a market cap of $339.91 million, a price-to-earnings ratio of -3.50 and a beta of 0.82. The firm's fifty day moving average is $1.22 and its 200 day moving average is $1.33. Esperion Therapeutics has a fifty-two week low of $0.69 and a fifty-two week high of $3.94.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of ESPR. Sivia Capital Partners LLC purchased a new position in shares of Esperion Therapeutics during the second quarter valued at $25,000. North Star Investment Management Corp. purchased a new position in Esperion Therapeutics during the second quarter valued at approximately $25,000. Meridian Wealth Management LLC bought a new position in Esperion Therapeutics in the first quarter worth approximately $29,000. Synergy Asset Management LLC boosted its position in Esperion Therapeutics by 3,496.3% during the 1st quarter. Synergy Asset Management LLC now owns 31,000 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 30,138 shares in the last quarter. Finally, Boomfish Wealth Group LLC increased its holdings in shares of Esperion Therapeutics by 29.5% in the 2nd quarter. Boomfish Wealth Group LLC now owns 45,306 shares of the biopharmaceutical company's stock valued at $45,000 after acquiring an additional 10,309 shares during the period. 47.39% of the stock is currently owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.